CN1613876A - Three spiral lentinan with anti-cancer activity and its preparation and use - Google Patents
Three spiral lentinan with anti-cancer activity and its preparation and use Download PDFInfo
- Publication number
- CN1613876A CN1613876A CN 200410060850 CN200410060850A CN1613876A CN 1613876 A CN1613876 A CN 1613876A CN 200410060850 CN200410060850 CN 200410060850 CN 200410060850 A CN200410060850 A CN 200410060850A CN 1613876 A CN1613876 A CN 1613876A
- Authority
- CN
- China
- Prior art keywords
- triple helical
- lentinan
- centrifugal
- polysaccharide
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to three-spiral lentina with beta-(1-3)-D-glucan having 20-30%(1-6) chain connected glucose side chains as main chain. It shows three chains in water, with average molecular weight of 20,000-200,000. It is produced by: cutting dry shiitake, removing fat by Suo extraction, soaking in normal saline, centrifuging, extracting remains at 100-130 degrees C, centrifuging, extracting remains in water solution of NaOH/NaBH4, adding acetic acid into extracting liquid to neutralize, decoloring supernatant, removing free protein, dialyzing, concentrating, and frozen drying. It has higher anti-tumor activity and can be used to prepare medicines or health-care products for improving immune ability and antitumor.
Description
Technical field
The present invention relates to a kind ofly have anti-tumor activity and get triple helical lentinan and its production and use.It belongs to the Polymer Physics field, also belongs to field of biology.
Background technology
At the beginning of the sixties, Chihara finds that the polysaccharide that extracts has anti-tumor activity (Nature, 1969,222,687 from mushroom fruiting body; 1970,225,943; Cancer Res., 1970,30,2776.), polysaccharide research after this is subjected to very big attention.Studies show that since the eighties, fungus polysaccharide is a kind of immunomodulator, it can strengthen scavenger cell and leukocytic phagocytic function, induce to produce tumour necrosis factor (TNF) and leukin, thereby improve the immunity function of human body, to the disease of multiple harm humans health, all has certain curative effect as immunologic derangement, cancer, diabetes, hypertension, hepatitis, pneumonia etc., and normal cell there is not toxic side effect (Intern.J.Orient.Med.17,57,1992).Mushroom belongs to fungi, is the local product resource of China, is used for Chinese medicine preparation for a long time, is used as miraculous cure on traditional medicine.But mushroom fruiting body directly is used as Chinese medicine, and curative effect is restricted.Because contain multiple polysaccharide in the mushroom, comprise mixed polysaccharide, alpha-glucan, beta-glucan, and change that the part polysaccharide is to lean on the method that decocts of common Chinese to extract with extraction conditions.
Summary of the invention
The purpose of this invention is to provide a kind of triple helical lentinan with anti-tumor activity and its production and use, prepared triple helical lentinan has higher anti-tumor activity, and the preparation method is simple, lower cost.
For achieving the above object, the technical solution adopted in the present invention is as follows: a kind of triple helical lentinan with anti-tumor activity, main chain is β-(1 → 3)-D-dextran, the glucose side group that contains 20～30% (1 → 6) keyed jointing, it is the triple helical chain conformation in the aqueous solution, its persistence length q is 80～120nm; Unit encloses long molar mass M
LBe 2000～2300nm
-1Pitch h is 0.30～0.32nm; Rootmean-square rotation radius＜s
2 z 1/2With weight-average molecular weight M
wBetween dependence:＜s
2 z 1/2=KM
w αIndex α in the equation is 0.8～1; Weight-average molecular weight is 200,000～2,000,000.
In preferred version of the present invention, above-mentioned triple helical lentinan also contains 0～20% conjugated protein.
The present invention also provides the preparation method of above-mentioned triple helical lentinan, and (Lentinusedodes) shreds with the exsiccant mushroom fruiting body, carries out Soxhlet with ethyl acetate, acetone successively and extracts removal fat, is immersed in then in the physiological saline, and is centrifugal; Residue extracts down at 100～130 ℃, and is centrifugal, collects residue; Residue is with 0.3～6wt%NaOH/0.01～0.05wt%NaBH
4The aqueous solution extract centrifugal extracting solution at normal temperatures; In extracting solution, add acetic acid and be neutralized to pH6～8, collect supernatant liquor; Supernatant liquor H
2O
2Decolouring is removed free protein with the Sevag method; Respectively with clear water and redistilled water dialysis, concentrate then, lyophilize gets the triple helical lentinan.
The present invention utilizes biotechnology, extraction separation goes out to have the mushroom triple helical polysaccharide of obvious anti-tumor activity and immunity function from the mushroom fruiting body that different spawn culture obtain, understand simultaneously it the firsts and seconds structure and and biological activity such as antitumor between relation.Simple, the lower cost of method therefor.The present invention utilizes the theoretical and chain conformation of method research mushroom triple helical polysaccharide in solution of Polymer Physics; Prepared triple helical lentinan has higher anti-tumor activity, can be used for preparation and improves immunity function and anti-tumor drug or healthcare products.
Show that by the biological activity result who the mouse of implanting Sarcoma 180 tumours is carried out abdominal injection experiment in the body mushroom triple helical polysaccharide of the present invention has the obvious suppression effect to tumour cell, even surpass the effect (50%) of chemicals 5-Fu.After the triple helical chain was destroyed, it did not show anti-tumor activity substantially, and it is very important to show that chain rigidity has play a part in anti-tumor activity.Especially, in right amount conjugated protein exists and helps the anti-tumor activity raising in the triple helical polysaccharide.The growth of external stomach cancer cell and cervical cancer cell Hela and the test-results of propagation show that lentinan is selective to tumour cell, promptly stomach cancer cell are had remarkable restraining effect, and to the basic unrestraint effect of Hela cell.The antiproliferative experimental result that the mushroom triple helical is carried out human body acute leukemia poison cell (HL-60) and human breast cancer cell (MCF-7) more shows that it has significant inhibition effect to propagation simultaneously, and can not destroy the propagation of normal monkey-kidney cells.
Embodiment
Below in conjunction with concrete example technical scheme of the present invention is described further:
Embodiment 1
Buy commercially available Suizhou, Hubei and produce mushroom fruiting body, the mushroom fruiting body fragment is carried out Soxhlet with ethyl acetate, acetone successively extracted each 8 hours.At room temperature extract three times with the 0.9%NaCl aqueous solution then: be immersed in the 0.9%NaCl aqueous solution and spend the night, centrifugal, collect residue.Residue extracts three times with hot water (100 ℃), and is centrifugal each half an hour, collects residue; Residue is used 0.4%NaOH/0.02%NaBH successively
4, 0.8%NaOH/0.02%NaBH
4And 5%NaOH/0.05%NaBH
4The aqueous solution extracts once under room temperature, and is centrifugal, collects supernatant liquor.Under room temperature, be neutralized to pH=7 with the 1M HOAc aqueous solution, centrifugal, collect supernatant liquor.After the supernatant concentration, all use 30%H
2O
2Decolouring is removed free protein to light yellow with the Sevag method, carries out more than 9 times repeatedly.Then, dialysed 5 days and 3 days through regenerated cellulose film with clear water and redistilled water respectively, concentrate, last lyophilize gets the pure product of triple helical polysaccharide (L-FV-IB).Detect intrinsic viscosity, weight-average molecular weight and all square rotation radius of each polysaccharide sample with viscometer, scattering of light and with the chromatograph joint used instrument of size exclusion, theoretical and method and computer simulation according to macromolecular solution calculate and characterize polymer at solution medium-chain molecular parameter.Draw lentinan thus and in the aqueous solution, present the triple helical chain conformation, and in DMSO, be sub-thread ball of string chain.In addition lentinan is dissolved among the DMSO, makes its triple helical chain be broken to strand, add precipitation agent acetone again product is precipitated and isolated, then with the acetone thorough washing remove DMSO, vacuum-drying obtains the strand lentinan.L-FV-IB is dissolved in the water with polysaccharide, becomes the different molecular weight fraction through ultrasonic degradation, is precipitation agent again with acetone, fraction with each fraction separated component amount narrowly distributing, last lyophilize obtains lentinan fraction (L-FV-IB21, L-FV-IB22, the L-FV-IB31 of different molecular weight and narrowly distributing, L-FV-IB41, L-FV-IB32, L-FV-IB52, L-FV-IB62, L-FV-IB43, L-FV-IB73).Sample L-FV-IB21 and L-FV-IB31 are dissolved in DMSO makes triple helical be broken to strand, be that precipitation agent comes out its precipitate and separate in order to acetone then, remove DMSO with the acetone thorough washing again, vacuum-drying prepares strand sample L-FV-IB21D and L-FV-IB31D thus.
With the content of carbohydrate in the phenol sulfonic acid method mensuration polysaccharide, determine its chemical constitution and structure with infrared, gas-chromatography.Measure its intrinsic viscosity ([η]) and weight-average molecular weight (M with the chromatograph joint used instrument of viscometer, scattering of light and scattering of light-size exclusion
w).Lentinan (L-FV-IB) and each fraction thereof molecular weight, intrinsic viscosity and conformation parameter (q, the persistence length in the 0.9%NaCl aqueous solution and DMSO; M
L, unit encloses long molar mass; H, pitch) for details see attached table 1.Draw thus, the molecular weight of L-FV-IB in the aqueous solution is its in DMSO three times, and conformation parameter theoretical by macromolecular solution and that computer simulation obtains meets the model parameter of triple helical chain.Show that thus L-FV-IB presents the triple helical chain conformation in the aqueous solution, and is sub-thread ball of string chain in DMSO.
Mushroom fruiting body triple helical polysaccharide intrinsic viscosity [η], molecular weight M 25 ℃ time the in the 0.9%NaCl aqueous solution and DMSO produced in Suizhou, subordinate list 1. Hubei
wAnd conformation parameter.
| Weight-average molecular weight * intrinsic viscosity sample 10 -5????(mL/g) | Unit encloses (nm) M of long persistence length pitch n molar mass q (nm) L(nm -1) |
| ??L-FV-IB??????8.8?????508 ???????????????2.8 a???63 a??L-FV-IB21????18.4????1630 ??L-FV-IB22????16.5????1480 ??L-FV-IB31????14.9????1170 ??L-FV-IB41????11.4????950 ??L-FV-IB32????9.79????725 ??L-FV-IB52????5.71????405 ??L-FV-IB62????5.27????336 ??L-FV-IB43????4.2?????- ??L-FV-IB73????3.57????202 | ?100????2200?????0.31 |
A: the value in DMSO
Mushroom triple helical polysaccharide L-FV-IB and strand polysaccharide L-FV-IBD series sample the results are shown in subordinate list 2 to what implant intravital Sarcoma 180 tumor control rates of BALB/c mouse.
Subordinate list 2. commercially available Hubei Sui Zhou produce the activity test result of Sarcoma 180 tumours in the anti-BALB/c mouse body of mushroom fruiting body triple helical polysaccharide.
| Sample | Weight-average molecular weight * 10 -5 | Conformation | Dosage (mg/kg * sky) | Inhibiting rate (%) | Body weight gain rate (%) | Complete inhibiting rate |
| ?5-Fu | ????60×8 | ??50.5 | ??12.6 | ??0/10 | ||
| ?L-FV-IB12 | ????21.6 | Triple helical | ????20×8 | ??23.0 | ??36.1 | ??0/10 |
| ????60×8 | ??34.6 | ??38.3 | ??0/10 | |||
| ?L-FV-IB21 | ????18.4 | Triple helical | ????20×8 | ??31.2 | ??33.7 | ??0/10 |
| ????60×8 | ??36.3 | ??31.9 | ??0/10 | |||
| ?L-FV-IB31 | ????14.9 | Triple helical | ????20×8 | ??28.6 | ??42.2 | ??0/10 |
| ????60×8 | ??49.5 | ??42.4 | ??0/10 | |||
| ?L-FV-IB21D | ????5.59 | The sub-thread random coil | ????20×8 | ??12.8 | ??33.2 | ??0/10 |
| ????60×8 | ??16.8 | ??33.4 | ??0/10 | |||
| ?L-FV-IB31D | ????4.37 | The sub-thread random coil | ????20×8 | ??8.1 | ??41.1 | ??0/10 |
| ????60×8 | ??12.3 | ??40.1 | ??0/10 |
Annotate: the mushroom beta-glucan with triple helical chain is when molecular weight hangs down relatively such as L-FVIB31, and it shows obvious anti-S-180 tumor promotion.But its anti-tumor activity disappears substantially after triple helical is broken to the sub-thread chain, as L-FV-IB21D and L-FV-IB31D.
Obviously, this polysaccharide has molecular weight and dose-dependently to implanting intravital Sarcoma 180 tumor control rates of BALB/c mouse.Show during high dosage that molecular weight is 14.9 * 10 than high anti-tumor activity
5Fraction L-FV-IB31 the S-180 tumour cell is demonstrated inhibiting rate up to 49.5%, near the value (50%) of 5-Fu, and with control group difference highly significant.And after triple helical was broken to the sub-thread chain, its anti-tumor activity disappeared substantially, as sample L-FV-IB21D and L-FV-IB31D.The external activity experiment shows that also the mushroom fruiting body polysaccharide has significant inhibition effect to the propagation of Sarcoma 180 tumour cells, and has dosage and molecular weight dependence (subordinate list 3).It is relative higher to the restraining effect of S-180 tumour cell and stomach cancer cell that the Hubei Sui Zhou that molecular weight is relatively little produces the lentinan sample, and molecular weight is 5.71 * 10
50 fraction L-FV-IB52 shows S-180 tumour cell and the strongest restraining effect of stomach cancer cell, and its inhibiting rate is respectively up to 45.3% and 56.2%.This polysaccharide also has selectivity to antitumor cell simultaneously, as its growth and no obvious suppression effect of propagation to cervical cancer cell Hela.
The Hubei Sui Zhou of subordinate list 3. different molecular weights produces the external anti-S-180 tumor promotion of mushroom fruiting body triple helical polysaccharide F-LV-IB.
| Sample | Dosage (mg/ml) | Inhibiting rate (%) |
| ????L-FV-IB11 | ????0.005 | ????-4.37 |
| ????0.05 | ????32.8 | |
| ????0.5 | ????30.8 | |
| ????L-FV-IB12 | ????0.005 | ????16.83 |
| ????0.05 | ????20.16 | |
| ????0.5 | ????25.21 | |
| ????L-FV-IB21 | ????0.005 | ????27.78 |
| ????0.05 | ????30.93 | |
| ????0.5 | ????32.54 | |
| ????L-FV-IB31 | ????0.005 | ????28.92 |
| ????0.05 | ????31.18 | |
| ????0.5 | ????36.11 | |
| ????L-FV-IB32 | ????0.005 | ????38.5 |
| ????0.05 | ????37.74 | |
| ????0.5 | ????41.06 | |
| ????L-FV-IB52 | ????0.005 | ????41.22 |
| ????0.05 | ????43.77 | |
| ????0.5 | ????45.32 | |
| ????L-FV-IB73 | ????0.005 | ????28.28 |
| ????0.05 | ????34.13 | |
| ????0.5 | ????43.44 |
Embodiment 2
Used mushroom fruiting body is encoded to No.2 by Hua Zhong Agriculture University fungal studies chamber with 4 kinds of its development, and No.36, the hybridization spawn culture of No.39 and No.50 obtain and openly externally sell (public can buy).Respectively 4 kinds of mushroom fruiting body fragments are carried out Soxhlet with ethyl acetate, acetone successively and extracted each 8 hours.At room temperature extract three times with the 0.9%NaCl aqueous solution then: be immersed in the 0.9%NaCl aqueous solution and spend the night, centrifugal, collect residue.Residue is used in hot water in the pressure kettle (120 ℃) and extracts three times, and is centrifugal each half an hour, collects residue; Residue 5%NaOH/0.05%NaBH
4The aqueous solution extracts once under room temperature, and is centrifugal, collects supernatant liquor.Under room temperature, be neutralized to pH6-8 with the 36%HOAc aqueous solution, centrifugal, collect supernatant liquor.After the supernatant concentration, use 30%H
2O
2Decolouring is removed free protein to light yellow with the Sevag method, carries out more than 9 times repeatedly.Then, dialysed 5 days and 3 days with clear water and redistilled water respectively, concentrate, last lyophilize gets the pure product of triple helical polysaccharide, called after: L-I successively
1, L-I
2, L-I
3, L-L
4. wherein contain conjugated protein and be respectively 5.8%, 5.5%, 5.2%, 15.2%.Wherein conjugated protein sloughed later polysaccharide be labeled as LNP-I respectively
1, LNP-I
2, LNP-I
3, LNP-I
4
Polysaccharide conformation characterizing method is with embodiment 1.4 kinds of triple helical lentinans intrinsic viscosity and weight-average molecular weight for details see attached table 4 in the aqueous solution.The molecular weight difference of the triple helical lentinan in the mushroom fruiting body of different strain, but its ratio in the aqueous solution and DMSO is 3,＜s
2Z
1/2=K M
w αIndex α in the equation is 0.8-0.91; And obtain its conformation parameter by the macromolecular solution Theoretical Calculation and be: persistence length q=85nm; Unit encloses long molar mass M
L=2300nm
-1Pitch h=0.315nm.The mushroom fruiting body polysaccharide that shows 4 kinds of different strains all presents the triple helical chain conformation in the aqueous solution, and all presents sub-thread random coil conformation in DMSO.Compare with embodiment 1, higher by the molecular weight of the triple helical polysaccharide that goes out of extraction separation in the mushroom fruiting body of hybridization spawn culture.
4 kinds of hybridization granulose samples the results are shown in subordinate list 4 to what implant intravital Sarcoma 180 tumor control rates of BALB/c mouse.Obviously, the triple helical polysaccharide that the present invention obtains shows higher anti-tumor activity, especially L-I
1, L-I
2And L-I
3Show higher anti-tumor activity, inhibiting rate even up to 70% considerably beyond the inhibiting rate (50%) of 5-Fu, and has dose-dependently.Remove the triple helical lentinan LNP-I after conjugated protein
1, LNP-I
2, LNP-I
3, LNP-I
4Active obviously reduce; After its triple helical chain was damaged, the anti-tumor activity (not shown) that disappears substantially showed that an amount of protein and triple-helix structure have material impact to its anti-tumor activity.4 kinds of polysaccharide L-I
1, L-I
2, L-I
3, L-I
4Propagation to human body acute leukemia poison cell (HL-60) and human breast cancer cell (MCF-7) also has significant inhibition effect, and can not destroy the propagation of normal monkey-kidney cells, shows that it does not have toxicity.Compare subordinate list 2 and 5 as can be known, the mushroom fruiting body spiral polysaccharide that is obtained by the hybridization spawn culture produces the higher biological activity of mushroom fruiting body triple helical lentinan demonstration than commercially available Suizhou, Hubei.Therefore, the triple helical lentinan can be used for preparing the healthcare products of antitumor drug and enhance immunity function, has great promotion and application prospect.
Subordinate list 4. hybridization bacterial classification mushroom fruiting body triple helical polysaccharide are intrinsic viscosity, the weight-average molecular weight 25 ℃ the time in the 0.9%NaCl aqueous solution, and anti-S-180 tumor promotion in the anti-BALB/c mouse body.
Sample character viscosity number weight average molecule molecular chain
The dosage inhibiting rate, the body weight gain rate,
(milliliter/gram) amount * 10
-5Number of share of stock (mg/kg * sky) is (%) (%)
L-I
1????1050????????14.4????????2.9????????20×7?????????????12.1??????55.0
60×7?????????????47.8??????29.1
L-I
2????1123????????16.4????????3.1????????20×7?????????????25.9??????41.3
30×7?????????????40.7??????34.7
60×7?????????????54.5??????31.4
L-I
3????1162????????16.5????????2.9????????20×7?????????????70.0??????27.4
30×7?????????????63.0??????37.1
60×7?????????????50.0??????42.7
L-I
4????1250????????17.7????????3.2????????20×7?????????????20.3??????33.3
30×7?????????????31.8??????46.1
60×7?????????????37.1??????45.0
5-fluorine urea 20 * 7 48.6 39.1
Pyrimidine
Blank to 44.2
According to group
Claims (4)
1. triple helical lentinan with anti-tumor activity, main chain is β-(1 → 3)-D-dextran, contains the glucose side group of 20～30% (1 → 6) keyed jointing, and it is the triple helical chain conformation in the aqueous solution, and its persistence length q is 80～120nm; Unit encloses long molar mass M
LBe 2000～2300nm
-1Pitch h is 0.30 ± 0.32nm; Weight-average molecular weight is 200,000～2,000,000.
2. triple helical lentinan according to claim 1 is characterized in that: contain 0～20% conjugated protein.
3. the preparation method of the described triple helical lentinan of claim 1 is characterized in that: the exsiccant mushroom fruiting body shredded, carries out Soxhlet with ethyl acetate, acetone successively and extract and remove fat, be immersed in then in the physiological saline, and centrifugal; Residue extracts down at 100～130 ℃, and is centrifugal, collects residue; Residue is with 0.3～6wt%NaOH/0.01～0.05wt%NaBH
4The aqueous solution at room temperature extract centrifugal extracting solution; In extracting solution, add acetic acid and be neutralized to pH6～8, collect supernatant liquor; Supernatant liquor H
2O
2Decolouring after the Sevag method is removed free protein, with clear water and redistilled water dialysis, concentrates respectively, and lyophilize obtains the triple helical lentinan.
4. the described triple helical lentinan of claim 1 or the medicine of raising immunity function or application in healthcare products antitumor in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100608507A CN1296389C (en) | 2004-09-14 | 2004-09-14 | Three spiral lentinan with anti-cancer activity and its preparation and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100608507A CN1296389C (en) | 2004-09-14 | 2004-09-14 | Three spiral lentinan with anti-cancer activity and its preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1613876A true CN1613876A (en) | 2005-05-11 |
| CN1296389C CN1296389C (en) | 2007-01-24 |
Family
ID=34764361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100608507A Expired - Fee Related CN1296389C (en) | 2004-09-14 | 2004-09-14 | Three spiral lentinan with anti-cancer activity and its preparation and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1296389C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002113A (en) * | 2010-12-08 | 2011-04-06 | 江南大学 | Method for preparing tea plant mushroom fruit body polysaccharide |
| CN101503477B (en) * | 2008-09-28 | 2011-10-19 | 武汉理工大学 | Method for extracting triple helix Dictyophora phalloidea polysaccharide |
| CN102408495A (en) * | 2011-12-29 | 2012-04-11 | 武汉大学 | Champignon beta-glucan having anti-inflammation activity, and preparation method and application thereof |
| CN103044566A (en) * | 2013-01-04 | 2013-04-17 | 合肥工业大学 | Method for preparing antioxidant polysaccharide from dictyophora indusiata aqueous extract residues |
| CN103981201A (en) * | 2014-05-30 | 2014-08-13 | 武汉大学 | Beta-glucan gene vector, and preparation method and application thereof |
| CN105001351A (en) * | 2015-08-31 | 2015-10-28 | 桂林茗兴生物科技有限公司 | Lentinan extraction method |
| WO2017005134A1 (en) * | 2015-07-03 | 2017-01-12 | 暨南大学 | Preparation method and use of linseed polysaccharide having antiviral and immunological activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1032428C (en) * | 1992-08-15 | 1996-07-31 | 樊菊芬 | Technology for extracting Xianggu mushroom saccharide and Xianggu mushroom fungus saccharide |
| CN1143866C (en) * | 2000-03-20 | 2004-03-31 | 武汉迪普生物技术有限公司 | Process for separating and purifying lentinan |
| CN1126547C (en) * | 2000-07-19 | 2003-11-05 | 南京振中生物工程有限公司 | Freeze dried lentinan holoside powder injecta and its preparation |
| NO20014256D0 (en) * | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
-
2004
- 2004-09-14 CN CNB2004100608507A patent/CN1296389C/en not_active Expired - Fee Related
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101503477B (en) * | 2008-09-28 | 2011-10-19 | 武汉理工大学 | Method for extracting triple helix Dictyophora phalloidea polysaccharide |
| CN102002113A (en) * | 2010-12-08 | 2011-04-06 | 江南大学 | Method for preparing tea plant mushroom fruit body polysaccharide |
| CN102408495A (en) * | 2011-12-29 | 2012-04-11 | 武汉大学 | Champignon beta-glucan having anti-inflammation activity, and preparation method and application thereof |
| CN102408495B (en) * | 2011-12-29 | 2013-09-18 | 武汉大学 | Champignon beta-glucan having anti-inflammation activity, and preparation method and application thereof |
| CN103044566A (en) * | 2013-01-04 | 2013-04-17 | 合肥工业大学 | Method for preparing antioxidant polysaccharide from dictyophora indusiata aqueous extract residues |
| CN103044566B (en) * | 2013-01-04 | 2015-07-01 | 合肥工业大学 | Method for preparing antioxidant polysaccharide from dictyophora indusiata aqueous extract residues |
| CN103981201A (en) * | 2014-05-30 | 2014-08-13 | 武汉大学 | Beta-glucan gene vector, and preparation method and application thereof |
| WO2017005134A1 (en) * | 2015-07-03 | 2017-01-12 | 暨南大学 | Preparation method and use of linseed polysaccharide having antiviral and immunological activity |
| US10835552B2 (en) | 2015-07-03 | 2020-11-17 | Jinan University | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide |
| CN105001351A (en) * | 2015-08-31 | 2015-10-28 | 桂林茗兴生物科技有限公司 | Lentinan extraction method |
| CN105001351B (en) * | 2015-08-31 | 2018-02-16 | 桂林茗兴生物科技有限公司 | The extracting method of lentinan |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1296389C (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Advances in lentinan: Isolation, structure, chain conformation and bioactivities | |
| Carbonero et al. | Lentinus edodes heterogalactan: Antinociceptive and anti-inflammatory effects | |
| Chakraborty et al. | Bioactive polysaccharides from natural sources: A review on the antitumor and immunomodulating activities | |
| Abdel-Gawad et al. | Technology optimization of chitosan production from Aspergillus niger biomass and its functional activities | |
| Ruthes et al. | D-Glucans from edible mushrooms: A review on the extraction, purification and chemical characterization approaches | |
| Ruthes et al. | Lactarius rufus (1→ 3),(1→ 6)-β-D-glucans: Structure, antinociceptive and anti-inflammatory effects | |
| Sarangi et al. | Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans | |
| Dalonso et al. | β-(1→ 3),(1→ 6)-Glucans: medicinal activities, characterization, biosynthesis and new horizons | |
| Silveira et al. | Structural characterization and anti-inflammatory activity of a linear β-D-glucan isolated from Pleurotus sajor-caju | |
| Chen et al. | Chain conformation and anti-tumor activity of derivatives of polysaccharide from Rhizoma Panacis Japonici | |
| Huang et al. | Preparation, chain conformation and anti-tumor activities of water-soluble phosphated (1→ 3)-α-d-glucan from Poria cocos mycelia | |
| Mou et al. | Chain conformation, physicochemical properties of fucosylated chondroitin sulfate from sea cucumber Stichopus chloronotus and its in vitro fermentation by human gut microbiota | |
| Cai et al. | Characteristics and antifatigue activity of graded polysaccharides from Ganoderma lucidum separated by cascade membrane technology | |
| Yan et al. | Physiochemical properties and antitumor activities of two α-glucans isolated from hot water and alkaline extracts of Cordyceps (Cs-HK1) fungal mycelia | |
| Garcia et al. | Bioactive polysaccharides from medicinal mushrooms: A review on their isolation, structural characteristics and antitumor activity | |
| Chaudhari et al. | Therapeutic and industrial applications of curdlan with overview on its recent patents | |
| Yu et al. | Immunomodulatory activities of sulfated Cyclocarya paliurus polysaccharides with different degrees of substitution on mouse spleen lymphocytes | |
| CN105001352B (en) | Beta-1,3/1,6-glucan, preparation method therefor, and application thereof in preparing immune enhancement and anti-tumor medicine and functional food | |
| CN111285939B (en) | Artemisia annua polysaccharide with effects of resisting oxidation and regulating intestinal flora and preparation method and application thereof | |
| Zhang et al. | Fractionation, chemical characterization and immunostimulatory activity of β-glucan and galactoglucan from Russula vinosa Lindblad | |
| de Jesus et al. | Chemical characterization and wound healing property of a β-D-glucan from edible mushroom Piptoporus betulinus | |
| CN105011123A (en) | Functional food for preventing tumor and assisting in anti-tumor treatment and preparing method thereof | |
| Yang et al. | Characterization and antioxidant activity of a novel polysaccharide from Pholidota chinensis Lindl. | |
| JP2006516988A (en) | Pharmaceutical composition comprising an active agent and chitosan for sustained drug release or mucoadhesion | |
| Sobieralski et al. | Fungi-derived beta-glucans as a component of functional food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070124 Termination date: 20100914 |